PPARG and Hepatic fibrosis: By using PPARγ antagonist GW9662 and specific LV‐shRNA, we found that PPARγ inhibition significantly decreased the inhibitory roles of KLF14 overexpression in HSCs, and in vivo study confirmed that KLF14 overexpression ameliorated TAA‐induced liver fibrosis in PPARγ‐dependent manner.